Results of a 9-week study showed the efficacy of AVEENO® Skin Relief Lotions and the impact of patient preference in improving patient compliance:
9 out of 10 patients stayed with AVEENO®
Both lotions were highly effective in relieving itchy, extra-dry skin
- Patients chose to apply the product more often than required, leading to greater improvement in skin parameters
- Given the choice of whether or not to continue with AVEENO®, 9 out of 10 stayed with AVEENO®
Clinical trial to determine compliance to and efficacy of AVEENO® Skin Relief Gentle Scent® vs. fragrance-free lotions in subjects with moderate to severe itchy, dry skin1
To evaluate the impact of usage rates of a scented versus a fragrance-free body lotion on patient compliance and determine whether increased lotion usage leads to improved efficacy for parameters of moisturization and itch.
Sixty-one females, between the ages of 18 and 60, with moderate to severe dry skin with mild to moderate itch (Fitzpatrick Skin Types I-IV) completed this single-centre, evaluator blinded, randomized 9-week clinical study. Test products included: AVEENO SKIN RELIEF GENTLE SCENT® Moisturizing Lotion (Coconut) and AVEENO® Skin Relief Fragrance Free Moisturizing Lotion (Unscented).
Subjects were assigned AVEENO® Skin Relief Fragrance Free Body Wash in place of their normal body cleanser to use throughout the 9-week study period.
The 9-week study period was split up into 3 phases of product usage:
- Phase 1 (Weeks 0 to 3): Subjects were given a body lotion (Study product) to apply on legs and body twice daily.
- Phase 2 (Weeks 3 to 6): Subjects were instructed to use the same study product as in phase 1, however, with no fixed regimen (subjects can apply as often as they wished).
- Phase 3 (Weeks 6 to 9): Subjects were allowed to either continue using the study product, or switch to any other marketed lotion, with no fixed usage regimen (subjects can apply as often as they wished).
- Clinical Efficacy Grading
- Skicon 200EX Measurements
- Subject Self-Assessment Questionnaires-end of all phases Final Self-Assessment Questionnaires
Clinical parameters of itching, dryness, roughness and scaling showed significant improvements in Phase 1 (week 3 vs baseline - week 0) for both lotions.
Significant additional improvements in itch, dryness, roughness and scaling were observed when comparing Phase 3 to Phase 1 for both lotions.
Results showed significant percentage increases in mean application when comparing Phases 2 & 3 to Phase 1. Subjects applied more often during these phases (by choice), leading to greater improvement in clinical parameters.
SKICON measurements showed significant increases in moisturization in Phase 1 (week 0 vs week 3).
Subjects perceived significant improvements for all parameters in Phase 1 (week 3 vs baseline - week 0).
Significant improvements in various individual parameters were perceived during Phase 2 (week 6 vs week 3) and Phase 3 (week 9 vs week 3) when compared to Phase 1 data for both the scented and unscented products.